Brought to you by 
Taro gets co-development rights to NovaBiotics' Novexatin
27 Sep 2013
Executive Summary
Taro Pharmaceutical Industries Ltd.’s Taro Pharmaceuticals North America Inc. has licensed exclusive US co-development and marketing rights to NovaBiotics Ltd.’s (antibacterial and antifungal therapeutics) Phase IIb-ready Novexatin (NP213 peptide) for mild-to-moderate onychomycosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Taro gets co-development rights to NovaBiotics' Novexatin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice